Drug pricing transparency
Drug pricing transparency rules are landing on technology and AI companies faster than most legal teams anticipated, particularly those building pharmacy benefit platforms, prescription data pipelines, or AI-driven formulary tools. The U.S. Centers for Medicare and Medicaid Services, the Federal Trade Commission, and the U.S. Department of Health and Human Services Office of Inspector General each hold overlapping enforcement authority over pricing disclosure, algorithmic pricing conduct, and data intermediary practices in this sector. Compliance teams are currently stress-testing whether their pricing logic and output disclosures satisfy CMS machine-readable file requirements, not just their pharma clients' obligations.
Watch
- CMS Transparency in Coverage machine-readable file rules: do your products trigger them?
- FTC enforcement pattern targeting algorithmic pricing as potential unfair trade practice
- HHS OIG advisory opinion pipeline on AI-assisted drug pricing recommendations
- State-level price transparency mandates in California and Colorado with extraterritorial data pulls
Recent material activity in Technology, AI & Competition
Active monitoring in place across Technology, AI & Competition. Material developments related to drug pricing transparency will appear here as they are published.